Search
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalIt is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. … Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.[L36485]
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalThe PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … Hemophilia B is a blood disorder with an incidence of approximately once every 30,000 male births in all populations and ethnic groups [A31557].
Ansuvimab
go.drugbank.com/drugs/DB16385Approvedcompared ansuvimab, REGN-EB3, ZMapp, and [remdesivir], a nucleoside analogue designed to inhibit viral replication, showed ansuvimab and REGN-EB3 to be superior, with improved patient survival and faster … Infection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as
Vusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigationalon anti-PD-1 therapy. … on a PD-1-blocking antibody-based regimen.
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnIt also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Methyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedMethyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigational[L4168] It was approved for the same indications in Canada in June 2022. … [L4170] On August 8 2018, the U.S.
CX-052075
go.drugbank.com/drugs/DB31655Approved[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.